Since established in 2000, Suzhou Lixin Pharmaceutical CO., Ltd. has been aimed at develop the global normative dominant market of APIs and advanced intermediates, driven by technological innovation, taken the path of sustainable development, and gradually form a raw materials products system including anti-tumor, cardiovascular, anti-platelet and treatment of senile dementia and other areas. Lixin Pharmaceutical has already been the high-quality supplier of many global pharmaceutical companies, and also established long-term relationship with a number of well-known domestic and foreign pharmaceutical companies to achieve win-win cooperation.
Lixin Pharmaceutical focuses on the in-deep research, development and production of characteristical APIs in the field of major diseases, upholds the culture of scientific, rigorous and normative, advocates innovation, attaches importance to safety, environmental protection, low consumption, high quality of the original development and application of technology. Lixin already has more than 30 pieces of China, the United States, Europe and other regions of the international invention patents, and has formed an independent intellectual property system.
Besides consistently supplying high-quality APIs and key intermediates, Lixin provides all-in-one technical solutions including API development, quality research, crystal type and particle size study, standard and impurity reference materials according to customer's requirements. The company has obtained 3 DMF files, 3 CEP certificates, 5 NMPA new drug certificates and 8 domestic GMP certificates. At the same time, more than 20 products are under development and registration at home and abroad, which has laid a solid foundation for the company's rapid and efficient sustainable development
Lixin Pharmaceutical adheres to the global regulation and GMP system and continues to improve and strive for excellence. With a number of GMP workshop and chemical synthesis workshop and the supporting facilities, Suzhou Lixin has repeatedly passed the inspection conducted by NMPA, FDA, EDQM, EMA. Covering an area of 100 thousand square meter with a total investment of 360 million yuan, the Shandong Lixin factory have begun construction at 2017 which is in line with European and American norms, and the factory would be put into operation in 2018. Lixin will provide the best pharmaceutical services to global pharmaceutical companies through its continued healthy development.
Chinese
English